Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-acetyl cysteine for prevention and control of taxane-induced neuropathy in breast cancer
IRCT20120215009014N377Phase 3Completed
- Sponsor
- Hamadan University of Medical Sciences
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, triple-blind trial in chemotherapy-induced peripheral neuropathy (CIPN) comparing N-acetyl cysteine arm with Placebo arm (2 arms). Primary endpoint: Severity of neuropathy. Started Feb 2021; status: completed.
02
Drugs
acetylcysteine
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on IRCT20120215009014N377.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20120215009014N377.